AVBP ArriVent BioPharma, Inc.: institutional ownership and insider trading
163 funds reported holding $1.67B of ArriVent BioPharma, Inc. in their latest 13F filings; in Q2 2026 funds net bought $153M, with 33 new positions and 14 funds selling out; over the last 12 months insiders bought $0 and sold $13.0M on the open market.
Famous investors holding AVBP
- D. E. Shaw (D. E. Shaw & Co.): $30.3M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $15.2M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $8.28M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $2.01M, 0.0% of the portfolio
Largest institutional holders of AVBP
- SUVRETTA CAPITAL MANAGEMENT, LLC — $157M
- INFINITUM ASSET MANAGEMENT, LLC — $154M
- HHLR ADVISORS, LTD. — $136M
- BlackRock, Inc. (BLK) — $113M
- ORBIMED ADVISORS LLC — $105M
- FMR LLC — $96.5M
- Octagon Capital Advisors LP — $68.5M
- VANGUARD CAPITAL MANAGEMENT LLC — $61.7M
- Sofinnova Investments, Inc. — $58.9M
- STATE STREET CORP (STT, STT-PG) — $58.8M
Recent AVBP insider trades
- Dec 10, 2025: Hillhouse Investment Management, Ltd. sold 555,555 shares ($13.0M)
5%+ owners
- BlackRock, Inc.: 6.8% (Schedule 13G/A, filed Jul 27, 2026)
- FMR LLC: 6.8% (Schedule 13G/A, filed May 6, 2026)
- ORBIMED ADVISORS LLC: 5.8% (Schedule 13D/A, filed Oct 8, 2026)
- Vivo Opportunity, LLC: 5.0% (Schedule 13G, filed Oct 13, 2026)